Medgenics Inc (NASDAQ:GNMX) – Jefferies Group issued their FY2022 earnings per share estimates for Medgenics in a note issued to investors on Tuesday. Jefferies Group analyst M. Andrews expects that the biotechnology company will earn ($1.39) per share for the year.
Shares of Medgenics (GNMX) traded down $0.12 on Wednesday, hitting $2.27. The company’s stock had a trading volume of 165,200 shares, compared to its average volume of 301,752. Medgenics has a one year low of $0.98 and a one year high of $6.18. The firm has a market cap of $141.80, a price-to-earnings ratio of -2.28 and a beta of 1.10.
Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in shares of Medgenics by 515.8% in the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 78,400 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Medgenics by 433.7% in the 3rd quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 106,178 shares in the last quarter. Finally, Northern Capital Management LLC raised its position in shares of Medgenics by 43.6% in the 3rd quarter. Northern Capital Management LLC now owns 152,300 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 46,250 shares in the last quarter. 16.57% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “FY2022 Earnings Forecast for Medgenics Inc Issued By Jefferies Group (GNMX)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/fy2022-earnings-forecast-for-medgenics-inc-issued-by-jefferies-group-gnmx.html.
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.